Dr. Marina Caskey, MD
Claim this profileThe Rockefeller University
Studies HIV
Studies AIDS
3 reported clinical trials
4 drugs studied
Affiliated Hospitals
Clinical Trials Marina Caskey, MD is currently running
3BNC117-LS + 10-1074-LS
for HIV
Background: Antiretroviral therapy (ART) can suppress HIV to undetectable levels in people, but the virus rebounds quickly if the drug treatment is stopped; this is because HIV can remain dormant in a pool of blood cells called the persistent viral reservoir (PVR). Yet lifelong ART is expensive and can lead to serious side effects over the long term. Some drugs may be more effective at reducing the PVR. Objective: To see if 2 study drugs (3BNC117-LS and 10-1074-LS) are safe and if they can lower the number of HIV-infected blood cells in people with HIV who are on ART. Eligibility: People aged 18 to 70 years with HIV who are on ART. Design: Participants will be screened. They will have a physical exam and blood and urine tests. They will undergo leukapheresis. Leukapheresis is a procedure where blood is drawn from a needle in one arm. The blood will pass through a machine that separates out the white blood cells. The remaining blood will be given back through a second needle in the other arm. The study drugs or placebo (normal saline) will be administered 3 times at 20-week intervals. The drugs will be given through a tube attached to a needle inserted into a vein in the arm. This will take 1 hour. Some participants will receive only a saline solution. They will not know if they are getting the drugs or the placebo. Participants will undergo leukapheresis up to 4 more times during the study. Participants will have follow-up visits every 10 weeks until the study ends.
Recruiting0 awards Phase 1
HepB mAb19
for Chronic Hepatitis B
This is a first-in-human, placebo-controlled, single dose, dose-escalation phase 1 study to evaluate the safety, pharmacokinetics and antiviral activity of a highly potent neutralizing anti-HBV monoclonal antibody (mAb), HepB mAb19, which targets the S-protein in individuals with chronic hepatitis B (CHB) on nucleos(t)ide analog therapy (NRTI).
Recruiting0 awards Phase 11 criteria
More about Marina Caskey, MD
Clinical Trial Related1 year of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Marina Caskey, MD has experience with
- 3BNC117-LS
- 10-1074-LS
- Sterile Saline
- HepB MAb19
Breakdown of trials Marina Caskey, MD has run
Human Immunodeficiency Virus Infection
Hepatitis A
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Marina Caskey, MD specialize in?
Marina Caskey, MD focuses on HIV and AIDS. In particular, much of their work with HIV has involved treating patients, or patients who are undergoing treatment.
Is Marina Caskey, MD currently recruiting for clinical trials?
Yes, Marina Caskey, MD is currently recruiting for 2 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Marina Caskey, MD has studied deeply?
Yes, Marina Caskey, MD has studied treatments such as 3BNC117-LS, 10-1074-LS, Sterile Saline.
What is the best way to schedule an appointment with Marina Caskey, MD?
Apply for one of the trials that Marina Caskey, MD is conducting.
What is the office address of Marina Caskey, MD?
The office of Marina Caskey, MD is located at: The Rockefeller University, New York, New York 10065 United States. This is the address for their practice at the The Rockefeller University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.